ImmunoPrecise Antibodies Ltd.
IPA
$0.3918
-$0.0082-2.05%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.32% | -14.05% | -251.17% | 37.56% | 67.86% |
| Total Depreciation and Amortization | 2.69% | -10.13% | 208.85% | -23.88% | -9.43% |
| Total Amortization of Deferred Charges | -- | -- | -97.65% | -- | -- |
| Total Other Non-Cash Items | -298.93% | -143.28% | 387.99% | 6,771.43% | 228.44% |
| Change in Net Operating Assets | -202.13% | 66.73% | 91.10% | 267.78% | -54.87% |
| Cash from Operations | -12,251.13% | -221.38% | -18.09% | 81.24% | 99.53% |
| Capital Expenditure | 78.38% | -88.52% | -143.48% | 167.22% | 58.07% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -100.00% | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -667.38% | -112.65% |
| Cash from Investing | 79.29% | -30.06% | -149.79% | 125.16% | 74.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -31.29% | 2.72% | 20.94% | 15.04% | -1.64% |
| Issuance of Common Stock | -- | -- | 142,400.00% | 863.92% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 763.73% | 748.52% | 394.21% | 317.02% | -256.58% |
| Foreign Exchange rate Adjustments | -101.77% | 62.29% | -805.93% | -42.98% | -111.76% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.83% | 128.55% | 9.99% | 104.94% | 83.37% |
